PRESS RELEASES

Date Title View
Toggle Summary Chimerix Announces Fourth Quarter and Full Year 2015 Financial Results
- Company to hold conference call at 8:30am ET today - - Survival and other key data from AdVise and matched controls to be reviewed with regulators in Summer 2016 - DURHAM, N.C. , Feb. 29, 2016 (GLOBE NEWSWIRE) -- Chimerix, Inc. (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral
View HTML
Toggle Summary Chimerix to Announce Fourth Quarter and Full Year 2015 Financial Results on February 29, 2016
DURHAM, N.C. , Feb. 22, 2016 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that it will host a live conference call and audio webcast on Monday, February 29, 2016 at 8:30 a.m.
View HTML
Toggle Summary Chimerix Announces Presentation of Detailed Results From Phase 3 SUPPRESS Trial at BMT Tandem Meetings
Brincidofovir Shows On-Treatment Antiviral Effect in HCT Setting  Despite Trial Not Meeting Primary Endpoint Company to Host Conference Call on February 22 at 8:00 a.m. EST to Provide Additional Analyses and Plans for Further Clinical Development DURHAM, N.C. , Feb.
View HTML
Toggle Summary Detailed Results From SUPPRESS Trial of Brincidofovir to be Presented at BMT Tandem Meetings
Chimerix Management to Hold Conference Call to Discuss Results and Next Steps at 8:00 a.m. EST on February 22, 2016
View HTML
Toggle Summary Chimerix Presents Positive Results From Brincidofovir Pivotal Study in Animal Model for Smallpox
100 Percent Survival Demonstrated in Animals Treated Immediately With Brincidofovir at Time of Confirmed Infection
View HTML
Toggle Summary Chimerix to Present at the 34th Annual J.P. Morgan Healthcare Conference
DURHAM, N.C. , Jan. 05, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral antivirals to address unmet medical needs, today announced that M. Michelle Berrey , M.D., M.P.H., President and Chief Executive Officer of Chimerix , will present at the 34
View HTML
Toggle Summary Chimerix Announces Top-Line Results From Phase 3 SUPPRESS Trial of Brincidofovir
- SUPPRESS Did Not Achieve Primary Endpoint for Prevention of Clinically Significant CMV  Infection After HCT - - Detailed Data Analysis to Follow - - Company to Hold Conference Call Today at 8:30 a.m. ET - DURHAM, N.C. , Dec. 28, 2015 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical
View HTML
Toggle Summary Chimerix to Present at the 27th Annual Piper Jaffray Healthcare Conference
DURHAM, N.C. , Nov. 24, 2015 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral antivirals to address unmet medical needs, today announced that M. Michelle Berrey , M.D., M.P.H., President and Chief Executive Officer of Chimerix , will present at the 27
View HTML
Toggle Summary Chimerix to Present at Stifel 2015 Healthcare Conference
DURHAM, N.C. , Nov. 11, 2015 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral antivirals to address unmet medical needs, today announced that M. Michelle Berrey , M.D., M.P.H., President and Chief Executive Officer of Chimerix , and W.
View HTML
Toggle Summary Chimerix Announces Third Quarter 2015 Financial Results
Topline Data from SUPPRESS Trial of Brincidofovir for Prevention of Cytomegalovirus in Hematopoietic Cell Transplant Recipients Anticipated in Early 2016 Dosing Initiated in Phase 3 SUSTAIN and SURPASS Trials of Brincidofovir for Prevention of Cytomegalovirus Disease in Kidney Transplant Recipients
View HTML